昂利康：目前在研的创新药项目仅为ALK-N001

Core Viewpoint - The company, Anglikang (002940), has experienced a significant stock price fluctuation, with a cumulative increase of over 20% in closing prices over two consecutive trading days, indicating abnormal trading activity [1] Company Summary - The only innovative drug project currently under research by the company is ALK-N001, which received approval for clinical trial notification in April 2025 [1] - As of the date of this announcement, ALK-N001 is still in the Phase I clinical trial stage [1] Industry Summary - The research and development of innovative drugs are characterized by long cycles, high investment, and significant uncertainty [1]